30 results about "Salmonella vaccine" patented technology

OmpD of non-typhoidal Salmonella (NTS), e.g. as derivable from Salmonella Typhimurium, and immunogenic fragments thereof are proposed for use in treating or preventing NTS infection and / or disease. OmpD of S. paratyphi and fragments thereof are also now of interest for vaccine use.

The invention belongs to the technical field of animal bacteriosis gene engineering vaccines, particularly relates to strain construction, vaccine preparation and application of a recombined haemophilus parasuis attenuated salmonella vaccine strain without resistance makers and used for expressing a surface antigen hps 06257 of haemophilus parasuis, and aims to obtain a recombinant salmonella choleraesuis asd-C500 / pYA-06257 (the preservation number is CCTCC NO: M2013054) without resistance makers and used for expressing the surface antigen HPS 06257 of haemophilus parasuis. The recombinant bacteria is lack of an asd gene on a salmonella choleraesuis genome, and contains a recombinant plasmid pYA-06257 which can express the asd gene and an outer membrane antigen hps 06257 gene of haemophilus parasuis on the strain. The invention further discloses a construction method of the recombinant strain asd-C500 / pYA-06257 and a corresponding preparation method of the haemophilus parasuis attenuated salmonella vaccine, as well as application to the preparation of the haemophilus parasuis attenuated salmonella vaccine.

The invention belongs to the technical field of fish biological products and cultured fish disease prevention and control, and in particular relates to an aeromonas salmonicida inactivated vaccine and applications of the aeromonas salmonicida inactivated vaccine. The antigen of the inactivated vaccine is aeromonas salmonicida subsp.masoucida, and the bacterial strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on March 19, 2013, and is assigned with the accession number of CGMCC No.7335. The inactivated vaccine can effectively induce aquaculture fish to generate specific immune response, and provide effective protection, and a material for preparing the aeromonas salmonicida inactivated vaccine is low in cost and is safe to the environment and the host.

Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and / or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.

The present invention provides an attenuated Salmonella Enteritidis vaccine, wherein the antigen is the recombinant Salmonella Enteritidis vaccine strain with the deposit number of CGMCC NO.13251. The vaccine provided by the invention is safe and reliable, and does not cause the risk of dispersing; the conventional injection of the vaccine will cause stress and the absorption effect of the vaccine is not good, but the vaccine can be immunized by oral administration, and the possibility of the immunogen being degraded before reaching the intestinal mucosa is avoided. ; This vaccine integrates the carrier and the adjuvant, which can not only induce the body to produce humoral immunity, but also produce cellular immunity and mucosal immunity, which can not only prevent and control IBDV, but also prevent and control Salmonella infection to a certain extent; The production process is simple and convenient, the production cost is extremely low, and no protein purification is required, and the vaccine bacteria only need to be expanded and lyophilized, and then oral immunization can save labor costs.

The present invention relates to a novel nucleic acid sequence (HPV16 L1S) encoding antigenic HPV16 L1 protein as provided in SEQ ID NO: 1, wherein the said sequence has atleast one modified codon for optimum stability of recombinant plasmid vector when transformed in the prokaryotic micro-organism for improved immunogenicity of the resulting prokaryotic micro-organism. The invention further relates to constructing recombinant vectors pFS14nsdHPV16L1 and pFS14nsdHPV16 kan L1S harboring SEQ ID NO: 1, wherein the former carries Ampicillin and the latter, Kanamycin as a selection marker. The invention also relates to an attenuated strain of a prokaryotic micro-organism transformed with nucleic acid encoding HPV16 (Human Papillomavirus) major capsid protein and expressing the corresponding protein. In addition the invention discloses a process of producing a vaccine based on prokaryotic micro-organism for the treatment of papillomavirus infection and associated risk of cancer.

The invention belongs to the technical field of preparation of animal vaccine auxiliary preparations and relates to a method for preserving a salmonella choleraesuis vaccine strain and a special protective agent thereof. The method for preserving the salmonella choleraesuis vaccine strain deposited under liquid nitrogen conditions is obtained by screening and characterized in that a protective agent is added to a salmonella choleraesuis vaccine solution during the preservation of the salmonella choleraesuis vaccine strain. The protective agent is prepared from the following components in massratio: 2.5% of sucrose, 7% of glucan, 6% of dimethylacetamide, and 0.025% of methionine. The special protective agent is prepared from the following components in mass ratio: 2.5% of sucrose, 7% of glucan, 6% of dimethylacetamide, and 0.025% of methionine. The special protective agent has the effects of permeability, semi-permeability, non-permeability and anti-oxidation. A survival rate of different concentrations of vaccine bacteria at different preservation times under a selected protective agent formula has no significant difference, and the survival rate maintains 70% or higher.